David Malcom Rodman, Chief Medical Officer at Mineralys Therapeutics, Inc. (MLYS), sold 20,407 shares at $27.58 ($557K) on 2026-07-13, disclosed to the SEC on 2026-07-15.
Scheduled sale ($557k) by Chief Medical Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $27.58 | 14,058 | $388K | 69.6% |
| 2 | $26.61 | 6,349 | $169K | 30.4% |
| Total | $27.28 avg | 20,407 | $557K | 100% |
| Filing → |
| MLYS | SELL | 2026-07-10 | $66K | — | Filing → |
| MLYS | SELL | 2026-06-17 | $350K | — | Filing → |
| MLYS | SELL | 2026-06-12 | $206K | — | Filing → |